American International Group, Inc. Affimed N.V. Transaction History

American International Group, Inc.

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.66 - $1.29 $139 - $272	-211 Reduced 0.31%	68,634 $51,000
Q4 2022 Feb 10, 2023	BUY	$1.1 - $2.45 $1,465 - $3,263	1,332 Added 1.97%	68,845 $85,000
Q3 2022 Nov 14, 2022	BUY	$1.96 - $3.32 $1,869 - $3,167	954 Added 1.43%	67,513 $139,000
Q2 2022 Aug 12, 2022	BUY	$2.27 - $4.86 $20,257 - $43,370	8,924 Added 15.48%	66,559 $184,000
Q1 2022 May 13, 2022	SELL	$3.69 - $5.65 $14,966 - $22,916	-4,056 Reduced 6.57%	57,635 $252,000
Q4 2021 Feb 11, 2022	SELL	$5.37 - $7.07 $9,918 - $13,058	-1,847 Reduced 2.91%	61,691 $341,000
Q3 2021 Nov 12, 2021	SELL	$5.54 - $7.51 $8,359 - $11,332	-1,509 Reduced 2.32%	63,538 $393,000
Q2 2021 Aug 13, 2021	SELL	$7.78 - $11.4 $5,586 - $8,185	-718 Reduced 1.09%	65,047 $553,000
Q1 2021 May 07, 2021	BUY	$5.12 - $8.48 $83,681 - $138,597	16,344 Added 33.07%	65,765 $520,000
Q4 2020 Feb 12, 2021	BUY	$3.16 - $7.03 $2,486 - $5,532	787 Added 1.62%	49,421 $288,000
Q3 2020 Nov 04, 2020	BUY	$3.26 - $4.73 $12,218 - $17,728	3,748 Added 8.35%	48,634 $165,000
Q2 2020 Aug 12, 2020	BUY	$1.58 - $4.63 $2,133 - $6,250	1,350 Added 3.1%	44,886 $207,000
Q1 2020 May 04, 2020	SELL	$1.44 - $3.02 $3,620 - $7,592	-2,514 Reduced 5.46%	43,536 $69,000
Q4 2019 Feb 05, 2020	BUY	$2.25 - $3.07 $18,051 - $24,630	8,023 Added 21.1%	46,050 $126,000
Q3 2019 Nov 08, 2019	SELL	$2.67 - $3.65 $704 - $963	-264 Reduced 0.69%	38,027 $112,000
Q2 2019 Aug 23, 2019	BUY	$2.6 - $4.21 $99,556 - $161,205	38,291 New	38,291 $110,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $185M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.